RNU6-579P

Across TCGA pan-cancer cohorts, RNU6-579P RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated RNU6-579P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-579P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-579P expression acts as an unfavorable survival marker, although some lineages such as ESCA and OV show a favorable association.

LIHC, PAAD, and CHOL are the cancer types where RNU6-579P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.164	0.786	<.001	54	view →
PAAD	DFS	Tertile	All	0.128	0.472	<.001	45	view →
CHOL	DFS	Tertile	All	0.045	0.486	.009	45	view →
READ	OS	Tertile	All	0.183	0.828	<.001	36	view →
UCEC	OS	Tertile	All	0.731	0.879	.012	24	view →
ESCA	DFS	Quartile	IV	0.826	0.309	.040	12	view →
LGG	OS	Tertile	All	0.796	0.936	<.001	12	view →
KICH	DFS	Tertile	All	0.654	0.935	.007	9	view →
ACC	DFS	Tertile	All	0.195	0.748	.003	9	view →
SARC	DFS	Tertile	All	0.162	0.602	.001	9	view →
OV	DFS	Tertile	IV	0.830	0.425	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RNU6-579P–LIHC (OS)

Open the LIHC breakdown →